CHICAGO — Can spotting an emerging ESR1 mutation early and changing first-line drugs before progression improve outcomes in patients with hormone receptor (HR)–positive, human epidermal growth factor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback